Guntram Schernthaner

Summary

Country: Austria

Publications

  1. ncbi Increase in visfatin after weight loss induced by gastroplastic surgery
    Katarzyna Krzyzanowska
    Department of Internal Medicine I, Rudolfstiftung Hospital, Juchgasse 25, 1030 Vienna, Austria
    Obesity (Silver Spring) 14:1886-9. 2006
  2. ncbi [Success of blood pressure reduction in diabetic patients]
    G Schernthaner
    Medizinische Abteilung Rudolfstiftung Wien, Wien, Germany
    Dtsch Med Wochenschr 131:S247-51. 2006
  3. doi Impact of postprandial and fasting glucose concentrations on HbA1c in patients with type 2 diabetes
    G Schernthaner
    Department of Medicine I, Rudolfstiftung Hospital, Juchgasse 25, 1030 Vienna, Austria
    Diabetes Metab 36:389-94. 2010
  4. pmc Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial
    Guntram Schernthaner
    Rudolfstiftung Hospital Vienna, Vienna, Austria
    Diabetes Care 36:2508-15. 2013
  5. doi Cardiovascular risk and thiazolidinediones--what do meta-analyses really tell us?
    G Schernthaner
    Department of Medicine I, Rudolfstiftung Hospital, Vienna, Austria
    Diabetes Obes Metab 12:1023-35. 2010
  6. ncbi Is dyslipidaemia important if we control glycaemia?
    Guntram Schernthaner
    Department of Medicine I, Rudolfstiftung Hospital Vienna, Juchgasse 25, A 1030 Vienna, Austria
    Atheroscler Suppl 6:3-10. 2005
  7. ncbi [Progress in the prevention of type 2 diabetes]
    Guntram Schernthaner
    I Medizinische Abteilung, Krankenhaus Rudolfstiftung, Wien, Osterreich
    Wien Klin Wochenschr 115:745-57. 2003
  8. doi Diabetes and Cardiovascular Disease: Is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR
    Guntram Schernthaner
    Department of Medicine I, Rudolfstiftung Hospital Vienna, Vienna, Austria
    Wien Med Wochenschr 160:8-19. 2010
  9. ncbi [Hypertension]
    Guntram Schernthaner
    Medizinische Abteilung, Krankenanstalt der Stadt Wien, Wien, Osterreich
    Acta Med Austriaca 31:166-7. 2004
  10. ncbi GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients
    G Schernthaner
    Rudolfstiftung Hospital, Vienna, Austria
    Eur J Clin Invest 34:535-42. 2004

Detail Information

Publications85

  1. ncbi Increase in visfatin after weight loss induced by gastroplastic surgery
    Katarzyna Krzyzanowska
    Department of Internal Medicine I, Rudolfstiftung Hospital, Juchgasse 25, 1030 Vienna, Austria
    Obesity (Silver Spring) 14:1886-9. 2006
    ..To investigate whether visfatin concentrations are related to changes in body weight, this adipokine was measured in insulin-resistant severely obese patients before and after gastroplastic surgery...
  2. ncbi [Success of blood pressure reduction in diabetic patients]
    G Schernthaner
    Medizinische Abteilung Rudolfstiftung Wien, Wien, Germany
    Dtsch Med Wochenschr 131:S247-51. 2006
    ..While diuretics and ss-blockers have a prodiabetic effect, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers may prevent diabetes more effectively than the metabolically neutral calcium channel blockers...
  3. doi Impact of postprandial and fasting glucose concentrations on HbA1c in patients with type 2 diabetes
    G Schernthaner
    Department of Medicine I, Rudolfstiftung Hospital, Juchgasse 25, 1030 Vienna, Austria
    Diabetes Metab 36:389-94. 2010
    ..This study aimed to assess the relative contributions of postprandial and fasting glucose concentrations to overall hyperglycaemia...
  4. pmc Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial
    Guntram Schernthaner
    Rudolfstiftung Hospital Vienna, Vienna, Austria
    Diabetes Care 36:2508-15. 2013
    ..To evaluate the efficacy and safety of canagliflozin, a sodium glucose cotransporter 2 inhibitor, compared with sitagliptin in subjects with type 2 diabetes inadequately controlled with metformin plus sulfonylurea...
  5. doi Cardiovascular risk and thiazolidinediones--what do meta-analyses really tell us?
    G Schernthaner
    Department of Medicine I, Rudolfstiftung Hospital, Vienna, Austria
    Diabetes Obes Metab 12:1023-35. 2010
    ....
  6. ncbi Is dyslipidaemia important if we control glycaemia?
    Guntram Schernthaner
    Department of Medicine I, Rudolfstiftung Hospital Vienna, Juchgasse 25, A 1030 Vienna, Austria
    Atheroscler Suppl 6:3-10. 2005
    ..However, use of fibrates in combination with statins may pose an unacceptable risk of myopathy. Therefore, other strategies for combination therapy are needed to normalize lipids in patients with type 2 diabetes or metabolic syndrome...
  7. ncbi [Progress in the prevention of type 2 diabetes]
    Guntram Schernthaner
    I Medizinische Abteilung, Krankenhaus Rudolfstiftung, Wien, Osterreich
    Wien Klin Wochenschr 115:745-57. 2003
    ..Since many hypertensive patients are insulin-resistant and have an increased risk in developing type 2 diabetes, the protective effect of these classes of antihypertensive drugs might be explained by their antiinsulin-resistance effects...
  8. doi Diabetes and Cardiovascular Disease: Is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR
    Guntram Schernthaner
    Department of Medicine I, Rudolfstiftung Hospital Vienna, Vienna, Austria
    Wien Med Wochenschr 160:8-19. 2010
    ..Future ongoing outcome studies in more than 50,000 patients will clarify whether new antidiabetic drugs--not inducing hypoglycemia or weight gain--will further improve the prognosis of T2DM patients...
  9. ncbi [Hypertension]
    Guntram Schernthaner
    Medizinische Abteilung, Krankenanstalt der Stadt Wien, Wien, Osterreich
    Acta Med Austriaca 31:166-7. 2004
    ..The present article represents the recommendations of the Austrian Diabetes Association for the treatment of hypertension in diabetic patients according to current scientific evidence...
  10. ncbi GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients
    G Schernthaner
    Rudolfstiftung Hospital, Vienna, Austria
    Eur J Clin Invest 34:535-42. 2004
    ..The European GUIDE study is the first large-scale head-to-head comparison of two sulphonylureas designed for once-daily administration used under conditions of everyday clinical practice...
  11. ncbi Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial
    G Schernthaner
    Department of Medicine I, Rudolfstiftung Hospital, A 1030 Vienna, Austria
    J Clin Endocrinol Metab 89:6068-76. 2004
    ..HbA1c reduction is similar after pioglitazone and metformin monotherapies, but differences in FPG, plasma lipids, and adverse effects between the two compounds may influence decision-making in individual prescribers...
  12. doi Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors
    G Schernthaner
    Department of Medicine, Rudolfstiftung Hospital, Vienna, Austria
    Int J Clin Pract 63:912-29. 2009
    ..As specific agonists of peroxisome proliferator-activated receptor-gamma, thiazolidinediones have also demonstrated protective effects on a variety of atherosclerosis biomarkers and surrogate measures of cardiovascular disease...
  13. ncbi Kidney disease in diabetology
    Guntram Schernthaner
    NDT, Head of the Department of Medicine I, Rudolfstiftung Hospital, Vienna, Austria
    Nephrol Dial Transplant 22:703-7. 2007
  14. ncbi Effect of massive weight loss induced by bariatric surgery on serum levels of interleukin-18 and monocyte-chemoattractant-protein-1 in morbid obesity
    Gerit Holger Schernthaner
    Department of Internal Medicine II, Division of Angiology, Medical University of Vienna, Vienna, Austria
    Obes Surg 16:709-15. 2006
    ....
  15. doi Bariatric surgery in patients with morbid obesity and type 2 diabetes
    Guntram Schernthaner
    Department of Medicine I, Rudolfstiftung Hospital Vienna, Juchgasse 25, A 1030 Vienna, Austria
    Diabetes Care 31:S297-302. 2008
  16. doi Elevated Fetuin-A concentrations in morbid obesity decrease after dramatic weight loss
    Johanna Maria Brix
    Department of Medicine 1, Rudolfstiftung Hospital, Vienna, Juchgasse 25, Vienna, Austria
    J Clin Endocrinol Metab 95:4877-81. 2010
    ..The liver-secreted protein Fetuin-A is elevated in insulin resistance, is an independent predictor of type 2 diabetes and is associated with atherosclerosis...
  17. doi YKL-40 is elevated in morbidly obese patients and declines after weight loss
    Moritz Hempen
    Department of Medicine II, Medical University of Vienna, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Obes Surg 19:1557-63. 2009
    ..The present study aims to study the level of YKL-40 in MO patients before and after weight loss as well as to investigate the relationship between YKL-40, IR, MCP-1, and obesity...
  18. doi Increase of osteopontin plasma concentrations after bariatric surgery independent from inflammation and insulin resistance
    Georg Schaller
    Department of Internal Medicine I, Rudolfstiftung Hospital, Juchgasse 25, 1030, and Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
    Obes Surg 19:351-6. 2009
    ....
  19. ncbi Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients
    H P Kopp
    Department of Medicine 1, Rudolfstiftung Hospital, Juchgasse 25, A 1030 Vienna, Austria
    Arterioscler Thromb Vasc Biol 23:1042-7. 2003
    ..Elevated levels of C-reactive protein (CRP) and interleukin-6 (IL-6), indicating chronic subclinical inflammation, have been associated with features of the IRS and incident cardiovascular disease...
  20. doi Circulating angiopoietic cells and diabetic retinopathy in type 2 diabetes mellitus, with or without macrovascular disease
    Simon Brunner
    Department of Ophthalmology, Rudolf Foundation Clinic, Vienna, Austria
    Invest Ophthalmol Vis Sci 52:4655-62. 2011
    ....
  21. doi Thrombin generation in type 2 diabetes with albuminuria and macrovascular disease
    Leyla Ay
    Department of Internal Medicine I, Rudolfstiftung Hospital Vienna, Medical University of Vienna, Vienna, Austria
    Eur J Clin Invest 42:470-7. 2012
    ..Albuminuria is an indicator of cardiovascular morbidity and mortality in patients with type 2 diabetic mellitus (T2DM)...
  22. doi YKL-40 concentrations are not elevated in gestational diabetes
    Georg Schaller
    Department of Medicine I, Rudolfstiftung Hospital, Vienna, Austria
    Eur J Clin Invest 40:339-43. 2010
    ..The involvement of inflammatory mechanisms in GDM remains unclear. YKL-40 is a novel inflammatory marker that has been recently found to be associated with type 2 diabetes. This is the first study to investigate YKL-40 in GDM...
  23. pmc Endothelial progenitor cells are related to glycemic control in children with type 1 diabetes over time
    Thomas Hörtenhuber
    Department of Pediatric and Adolescent Medicine, Medical University of Vienna and Vienna General Hospital, Vienna, Austria
    Diabetes Care 36:1647-53. 2013
    ..We hypothesized that EPCs are modified in children with T1DM and are related to characteristics of T1DM such as glycemic control...
  24. ncbi Relationship of androgens to insulin resistance and chronic inflammation in morbidly obese premenopausal women: studies before and after vertical banded gastroplasty
    Hans Peter Kopp
    Department of Medicine I, Rudolfstiftung Hospital, Vienna, Austria
    Obes Surg 16:1214-20. 2006
    ....
  25. doi Circulating levels of MCP-1 are increased in women with gestational diabetes
    Katharina Klein
    Department of Obstetrics and Feto maternal Medicine, Medical University of Vienna, Vienna, Austria
    Prenat Diagn 28:845-51. 2008
    ..We investigated whether gestational diabetes mellitus is associated with monocyte-chemoattractant-protein-1 (MCP-1) and soluble CD40 ligand (sCD40L), the functional relevant proteins in the inflammatory process...
  26. ncbi Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes
    Katarzyna Krzyzanowska
    Department of Internal Medicine I, Rudolfstiftung Hospital, Juchgasse 25, 1030 Vienna, Austria
    Atherosclerosis 189:236-40. 2006
    ..Recent reports suggest a relationship between tHcy and ADMA. To evaluate the connection between ADMA and tHcy and macrovascular disease, we determined both risk factors in T2DM patients with and without macrovascular disease...
  27. doi High-molecular-weight adiponectin does not predict cardiovascular events in patients with type 2 diabetes
    Katarzyna Krzyzanowska
    Department of Internal Medicine I, Rudolfstiftung Hospital, Vienna, Austria
    Transl Res 153:199-203. 2009
    ..It is unlikely that HMW adiponectin has significant vasoprotective effects in these patients...
  28. ncbi Organ protection in the secondary prevention of type 2 diabetes
    Guntram Schernthaner
    Department of Medicine I, Rudolfstiftung Hospital, Vienna, Austria
    Drugs Today (Barc) 42:17-23. 2006
    ..Pioglitazone has furthermore demonstrated numerous antiatherogenic effects in clinical and preclinical investigations...
  29. pmc Renal function but not asymmetric dimethylarginine is independently associated with retinopathy in type 2 diabetes
    Katarzyna Krzyzanowska
    Internal Medicine 1, Rudolfstiftung Hospital, 1030 Vienna, Austria
    Cardiol Res Pract 2011:260191. 2011
    ..006). Conclusions. These findings indicate an association between ADMA and DR in T2DM independent of macrovascular disease. This relationship is modified by GFR, the only parameter significantly related to DR in multivariate analysis...
  30. doi YKL-40 in type 2 diabetic patients with different levels of albuminuria
    Johanna M Brix
    Rudolfstiftung Hospital Vienna, Medicine I, Vienna, Austria
    Eur J Clin Invest 41:589-96. 2011
    ..YKL-40 is also associated with both and elevated in nondiabetic vascular patients. We investigated YKL-40 and its association with vascular disease in type 2 diabetic patients with albuminuria...
  31. ncbi Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes
    Katarzyna Krzyzanowska
    Department of Internal Medicine I, Rudolfstiftung Hospital, Juchgasse 25, 1030 Vienna, Austria
    Diabetes Care 30:1834-9. 2007
    ..We hypothesized that ADMA predicts cardiovascular events and enhances risk prediction independent of established risk markers in patients with type 2 diabetes...
  32. doi Correlation of different circulating endothelial progenitor cells to stages of diabetic retinopathy: first in vivo data
    Simon Brunner
    Department of Ophthalmology, Rudolf Foundation Clinic Vienna, Vienna, Austria
    Invest Ophthalmol Vis Sci 50:392-8. 2009
    ..To investigate vasculogenic circulating progenitor cells (CPCs), endothelial progenitor cells (EPCs), and mature EPCs in patients with type 1 diabetes mellitus (T1DM) with or without diabetic retinopathy (DR)...
  33. doi [Lipid profiles and therapy status in the secondary prevention of high risk patients with cardiovascular disease and/or diabetes mellitus: the Austrian Hospital Screening Project (HSP)]
    Michael Roden
    1 Med Abteilung, Hanusch Krankenhaus, Karl Landsteiner Institut für Endokrinologie und Stoffwechsel, Wien, Austria
    Wien Klin Wochenschr 120:558-65. 2008
    ..With regard to national and international guidelines, there is still a need to improve the clinical practice of lowering LDL-C for secondary prevention in high risk patients in Austria...
  34. doi ADMA, cardiovascular disease and diabetes
    Katarzyna Krzyzanowska
    Department of Internal Medicine I, Rudolfstiftung Hospital, Vienna, Austria
    Diabetes Res Clin Pract 82:S122-6. 2008
    ..In addition, ADMA might not only be a risk marker but also a causative factor for cardiovascular disease. This review summarizes the literature on the relationship between ADMA, cardiovascular disease and diabetes...
  35. pmc Fetuin-A levels are increased in patients with type 2 diabetes and peripheral arterial disease
    David Peter Lorant
    Department of Medicine II, Medical University of Vienna, Vienna, Austria
    Diabetes Care 34:156-61. 2011
    ..In contrast, elevated fetuin-A is associated with cardiovascular events in non-renal patients. We investigated fetuin-A in patients with type 2 diabetes and peripheral arterial disease (PAD)...
  36. ncbi Increased visfatin concentrations in women with gestational diabetes mellitus
    Katarzyna Krzyzanowska
    Department of Internal Medicine I, Rudolfstiftung Hospital, Vienna, Austria
    Clin Sci (Lond) 110:605-9. 2006
    ..001). In conclusion, visfatin is elevated in women with GDM and increases during the course of pregnancy as well as after delivery. Furthermore, visfatin shows no association with insulin and leptin in women with GDM...
  37. ncbi Soluble CD40L in patients with morbid obesity: significant reduction after bariatric surgery
    G H Schernthaner
    Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
    Eur J Clin Invest 36:395-401. 2006
    ..As morbid obesity is closely associated with chronic inflammation and insulin resistance (IR), it was of interest to study sCD40L in patients with morbid obesity before and after massive weight loss induced by bariatric surgery...
  38. ncbi Metabolic control in patients with type 2 diabetes using Humalog Mix50 injected three times daily: crossover comparison with human insulin 30/70
    G Schernthaner
    Department of Medicine I, Rudolfstiftung Hospital, Vienna, Austria
    Horm Metab Res 36:188-93. 2004
    ..This study was designed to compare metabolic control with three daily injections of Humalog Mix50 or premixed human insulin 30/70 (30 % regular/70 % NPH) twice daily in accordance with normal prescription practice...
  39. ncbi Weight loss reduces circulating asymmetrical dimethylarginine concentrations in morbidly obese women
    Katarzyna Krzyzanowska
    Department of Internal Medicine I, Rudolfstiftung Hospital, 1030 Vienna, Austria
    J Clin Endocrinol Metab 89:6277-81. 2004
    ..The decrease of highly elevated ADMA concentrations in morbidly obese patients is paralleled by improvement of parameters associated with the metabolic syndrome after weight loss...
  40. doi [Diabetes Care Austria 2009: registry for type 2 diabetic patients in general practitioners' ordinations in Austria]
    Bernhard Ludvik
    Klinische Abteilung für Endokrinologie und Stoffwechsel, Universitätsklinik für Innere Medizin III, Medizinische Universität Wien, Wien, Austria
    Wien Klin Wochenschr 124:69-77. 2012
    ..2%. An insulin therapy was initialised late, but was nevertheless effective as shown by comparable HbA1c values in patients with a diabetes duration of 4 to more than 15 years...
  41. ncbi Insulin resistance and inflammation in the early phase of type 2 diabetes: potential for therapeutic intervention
    Gerit Holger Schernthaner
    Department of Internal Medicine II, Division of Angiology, Medical University Vienna, Austria
    Scand J Clin Lab Invest Suppl 240:30-40. 2005
    ....
  42. doi [The significance of long acting insulin analogues in the treatment of type 2 diabetes mellitus]
    Bernhard Ludvik
    Universitätsklinik für Innere Medizin III, Medizinische Universität Wien, Wien, Austria
    Wien Klin Wochenschr 121:473-82. 2009
    ..This position paper summarises up the current evidence concerning this subject...
  43. ncbi The effect of insulin treatment on HbA1c, body weight and lipids in type 2 diabetic patients with secondary-failure to sulfonylureas. A five year follow-up study
    S Kudlacek
    I. Med. Abteilung der Krankenanstalt Rudolfstiftung, II. Med. Univ. Klinik, Wien, Austria
    Horm Metab Res 24:478-83. 1992
    ..Furthermore, small increases of plasma creatinine from 88.4 microM to 115 microM, as well as systolic (19.3 kPa to 20.7 kPa) and diastolic (10.7 kPa to 11.3 kPa) blood pressures were observed.(ABSTRACT TRUNCATED AT 250 WORDS)..
  44. doi [Antihypertensive therapy in diabetes mellitus - 2012 guidelines of the Austrian Diabetes Association]
    Guntram Schernthaner
    1 Medizinische Abteilung, Krankenanstalt Rudolfstiftung, Wien, Osterreich
    Wien Klin Wochenschr 124:23-7. 2012
    ..Most patients with diabetes mellitus need antihypertensive combination therapies, whereby ACE-inhibitors or Angiotensin-II receptor antagonists should be first line drugs...
  45. doi YKL-40 is elevated in patients with peripheral arterial disease and diabetes or pre-diabetes
    Klaudija Batinic
    Division of Pediatric Cardiology, University Zurich, Switzerland
    Atherosclerosis 222:557-63. 2012
    ..Experimental in vivo and in vitro data suggest a role of YKL-40 in tissue remodeling. A disease modulating potency of YKL-40 was not investigated in peripheral arterial disease (PAD)...
  46. ncbi Gliclazide modified release: A critical review of pharmacodynamic, metabolic, and vasoprotective effects
    Guntram Schernthaner
    Department of Medicine I, Rudolfstiftung Hospital, Vienna, Austria
    Metabolism 52:29-34. 2003
    ..In addition, gliclazide MR shows the ability to inhibit key mechanisms in diabetic angiopathy, independently of glycemic control...
  47. pmc Reduced basal ATP synthetic flux of skeletal muscle in patients with previous acromegaly
    Julia Szendroedi
    1st Med Department and Karl Landsteiner Institute for Endocrinology and Metabolism, Hanusch Hospital, Vienna, Austria
    PLoS ONE 3:e3958. 2008
    ..As growth hormone (GH) excess can reduce insulin sensitivity, we examined the impact of previous acromegaly (AM) on glucose metabolism, lipid storage and muscular ATP turnover...
  48. doi Kidney disease in diabetology: lessons from 2007
    Guntram Schernthaner
    Guntram Schernthaner, Rudolfstiftung Hospital, A 1030, Juchgasse 25, Vienna, Austria
    Nephrol Dial Transplant 23:1112-5. 2008
  49. doi Thrombin generation in morbid obesity: significant reduction after weight loss
    L Ay
    Department of Internal Medicine I, Rudolfstiftung Hospital Vienna, Austria
    J Thromb Haemost 8:759-65. 2010
    ..Patients with morbid obesity (MO; body mass index > 40 kg m(-2)) suffer from an increased risk of cardiovascular disease, stroke, venous thromboembolism and all-cause mortality...
  50. pmc Serum concentrations of retinol-binding protein 4 in women with and without gestational diabetes
    K Krzyzanowska
    Department of Internal Medicine I, Rudolfstiftung Hospital, 1030, Vienna, Austria
    Diabetologia 51:1115-22. 2008
    ..Retinol-binding protein 4 (RBP4) could be related to insulin resistance. We hypothesised that RBP4 is elevated in gestational diabetes...
  51. ncbi Effects of marked weight loss on plasma levels of adiponectin, markers of chronic subclinical inflammation and insulin resistance in morbidly obese women
    H P Kopp
    Department of Medicine 1, Rudolfstiftung Hospital Vienna, Austria
    Int J Obes (Lond) 29:766-71. 2005
    ....
  52. ncbi Improvement of glucose tolerance in type 2 diabetic patients: traditional vs. modern insulin regimens (results from the Austrian Biaspart Study)
    H Abrahamian
    City Hospital Vienna Lainz, 3rd Medical Department, Vienna, Austria
    Horm Metab Res 37:684-9. 2005
    ....
  53. ncbi Asymmetrical dimethylarginine is related to renal function, chronic inflammation and macroangiopathy in patients with Type 2 diabetes and albuminuria
    K Krzyzanowska
    Department of Internal Medicine I, Rudolfstiftung Hospital, Medical University Vienna, Austria
    Diabet Med 24:81-6. 2007
    ..To determine the relationship between ADMA, renal albumin excretion rate (AER) and cardiovascular risk, we studied 103 T2DM patients...
  54. ncbi Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes
    N Eibl
    Rudolfstiftung Hospital, Vienna, Austria
    Eur J Clin Invest 34:205-9. 2004
    ..Our study attempts to clarify the effect of improved metabolic control on platelet activation markers in patients with type-2 diabetes...
  55. ncbi Circulating ADMA concentrations are elevated in hypopituitary adults with and without growth hormone deficiency
    K Krzyzanowska
    Department of Internal Medicine I, Rudolfstiftung Hospital, Juchgasse 25, 1030 Vienna, Austria
    Eur J Clin Invest 35:208-13. 2005
    ..We studied the concentrations of ADMA in hypopituitary patients with and without growth hormone deficiency (GHD) and in healthy subjects...
  56. ncbi Preprandial vs. postprandial insulin lispro-a comparative crossover trial in patients with Type 1 diabetes
    G Schernthaner
    Department of Internal Medicine, Rudolfstitung Hospital, Vienna, Austria
    Diabet Med 21:279-84. 2004
    ..Administration of bolus insulin after eating may be a useful therapeutic option for some patients. This 6-month, crossover study compared metabolic effects of routine use of preprandial vs. postprandial injection of bolus insulin lispro...
  57. ncbi Adiponectin concentrations increase during acute FFA elevation in humans treated with rosiglitazone
    K Krzyzanowska
    Department of Internal Medicine I, Rudolfstiftung Hospital, Vienna, Austria
    Horm Metab Res 39:769-72. 2007
    ..CRP and resistin were not affected by rosiglitazone or FFAs. The acute increase in circulating adiponectin concentrations during acutely elevated FFA depends on PPAR gamma activation in healthy subjects...
  58. ncbi [Angiotensin II type-1 receptor antagonists and diabetes mellitus]
    C Schnack
    I Medizinische Abteilung, Krankenanstalt Rudolfstiftung, Juchgasse 25, A 1030 Wien
    Wien Med Wochenschr 151:165-8. 2001
    ....
  59. ncbi A serine/alanine polymorphism in the nucleotide-binding fold-2 of the sulphonylurea receptor-1 (S1369A) is associated with enhanced glucose-induced insulin secretion during pregnancy
    W Krugluger
    Institute of Clinical Chemistry, Municipal Hospital Rudolfstiftung, Vienna, Austria
    J Inherit Metab Dis 23:705-12. 2000
    ..01, p=0.9). From our data we conclude that in PW with the alanine substitution in the NBF-2 region, the insulin response of the pancreatic beta-cell after glucose intake is enhanced and does not correlate with actual BG levels...
  60. ncbi Nondipping of nocturnal blood pressure is related to urinary albumin excretion rate in patients with type 2 diabetes mellitus
    S Equiluz-Bruck
    Department of Medicine I, Rudolfstiftung Hospital Vienna, Austria
    Am J Hypertens 9:1139-43. 1996
    ....
  61. ncbi High prevalence of abnormal circadian blood pressure regulation and impaired glucose tolerance in adults with hypopituitarism
    K Krzyzanowska
    Department of Internal Medicine I, Rudolfstiftung Hospital, Vienna, Austria
    Exp Clin Endocrinol Diabetes 113:430-4. 2005
    ..The high prevalence of nocturnal non-dipping and glucose intolerance detected in this cohort might contribute to the increased cardiovascular risk of hypopituitary patients...
  62. doi [Diabetic nephropathy--update 2012]
    Martin Auinger
    3 Medizinische Abteilung, Krankenhaus Hietzing der Stadt Wien, und Karl Landsteiner Institut für Stoffwechselerkrankungen und Nephrologie, Wien, Osterreich
    Wien Klin Wochenschr 124:42-9. 2012
    ..The present article represents the recommendations of the Austrian Diabetes Association and the Austrian Society for Nephrology for the prevention and treatment of diabetic nephropathy...
  63. ncbi Low levels of Sex-Hormone-Binding Globulin predict insulin requirement in patients with gestational diabetes mellitus
    H P Kopp
    Department of Medicine 1, Rudolfstiftung Hospital, Juchgasse 25, A 1030 Vienna, Austria
    Exp Clin Endocrinol Diabetes 109:365-9. 2001
    ..30; p <0.01). In summary, we found significantly lower levels of SHBG in patients with GDM, especially in those who developed severe GDM and required insulin therapy during the last months of pregnancy...
  64. pmc Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis
    G Schernthaner
    Department of Medicine I, Rudolfstiftung Hospital Vienna, Juchgasse 25, 1030, Vienna, Austria
    Diabetologia 53:1258-69. 2010
    ..This paper critically assesses the basis of the ADA/EASD algorithm and the resulting tiers of treatment options...
  65. doi The impact of risk factors and more stringent diagnostic criteria of gestational diabetes on outcomes in central European women
    A Kautzky-Willer
    Department of Endocrinology and Metabolism, Medical University of Vienna, Wahringer Gurtel 18 20, Vienna, Austria
    J Clin Endocrinol Metab 93:1689-95. 2008
    ....
  66. doi Diabetic nephropathy: new approaches for improving glycemic control and reducing risk
    Guntram Schernthaner
    Department of Medicine I, Rudolfstiftung Hospital, Vienna Austria
    J Nephrol 26:975-85. 2013
    ..The ongoing advances in T2DM therapy may allow optimization of glycemic control in a wide range of patients, thereby helping to reduce the increasing morbidity and mortality associated with diabetic nephropathy. ..
  67. ncbi Impaired primary immune response in type-1 diabetes: results from a controlled vaccination study
    Nicole Eibl
    Krankenanstalt Rudolfstiftung, 1 Medizinische Abteilung, Juchgasse 25, A 1030 Vienna, Austria
    Clin Immunol 103:249-59. 2002
    ....
  68. ncbi Compression of kidneys in Erdheim-Chester disease of retroperitoneum: Open surgical approach
    Thomas Florian Wimpissinger
    Department of Urology and Ludwig Boltzmann Institute for Extracorporeal Lithotripsy and Endourology, Rudolfstiftung Hospital, Vienna, Austria
    Urology 65:798. 2005
    ..After 3 years of follow-up, we have concluded that the open surgical approach is an option in the management of renal complications in Erdheim-Chester disease...
  69. ncbi Enhanced growth hormone responses to growth hormone releasing hormone in male type I diabetic patients
    P Pietschmann
    , Vienna, Austria
    Horm Metab Res 23:379-82. 1991
    ..The absence of an effect of sex on GHRH stimulated GH responses in type I diabetes mellitus provides further evidence of an abnormal GH secretion in this disorder...
  70. ncbi No effect of homocysteine-lowering therapy on vascular inflammation and haemostasis in peripheral arterial occlusive disease
    G H Schernthaner
    Department of Internal Medicine II, Medical University of Vienna, and Department of Internal Medicine I, Rudolfstiftung Hospital, Vienna, Austria
    Eur J Clin Invest 36:333-9. 2006
    ..Although peripheral arterial occlusive disease (PAOD) is significantly associated with elevated homocysteine levels, the clinical relevance of hyperhomocysteinaemia for the prevention and progression of PAOD is still unknown...
  71. ncbi Progress in the immunointervention of type-1 diabetes mellitus
    G Schernthaner
    Department of Medicine I, Rudolfstiftung Hospital Vienna, Vienna, Austria
    Horm Metab Res 27:547-54. 1995
    ..e. Coxsackie virus protein P2-c) could be adopted. If all these interventions are not effective in the long term run, research should be concentrated on molecular approaches after improvement in gene transfer technology...
  72. ncbi Increased growth hormone responses to growth hormone releasing hormone and thyrotropin releasing hormone in patients with metastatic testicular cancer
    P Pietschmann
    , Wien, Austria
    Horm Metab Res 22:109-13. 1990
    ..Our data suggest an alteration of hypothalamic and/or pituitary regulation of GH secretion in patients with metastatic testicular cancer...
  73. ncbi Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)
    Robert Wilcox
    Department of Cardiovascular Medicine, Queen s Medical Centre, University Hospital, Nottingham, UK
    Stroke 38:865-73. 2007
    ..Diabetes is an important risk factor for stroke. We conducted analyses in patients who had entered the PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) with a history of stroke or without stroke...
  74. pmc Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease
    Christian A Schneider
    Facharzt für Innere Medizin Kardiologie Klinik III für Innere Medizin, Zimmer 0, C, 329 Universität zu Köln Kerpener Strasse 68, 50937 Koln, Germany
    J Am Soc Nephrol 19:182-7. 2008
    ..Patients who had CKD and were treated with pioglitazone were less likely to reach a composite end point of all-cause death, MI, and stroke, independent of the severity of renal impairment...
  75. ncbi Peptide YY and glucagon-like peptide-1 in morbidly obese patients before and after surgically induced weight loss
    Thomas Reinehr
    Vestische Hospital for Children and Adolescents Datteln, University of Witten Herdecke, Dr F Steiner Str 5, 45711 Datteln, Germany
    Obes Surg 17:1571-7. 2007
    ..The aim of this study was to analyze the relationships between fasting PYY, GLP-1, and weight status in morbidly obese patients before and after surgically induced weight loss...
  76. ncbi Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment
    Dennis Heutling
    Department of Endocrinology and Metabolism, Otto von Guericke University, D 39120 Magdeburg, Germany
    J Clin Endocrinol Metab 93:82-90. 2008
    ..The endogenous nitric oxide synthase inhibitor asymmetrical dimethyl-L-arginine (ADMA) is associated with atherosclerosis and represents an independent marker for cardiovascular morbidity and mortality...
  77. doi Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials
    Nish Chaturvedi
    International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College Healthcare NHS Trust, London, UK
    Lancet 372:1394-402. 2008
    ..We therefore designed the DIabetic REtinopathy Candesartan Trials (DIRECT) Programme to assess whether candesartan could reduce the incidence and progression of retinopathy in type 1 diabetes...
  78. ncbi Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations
    Marc A Pohl
    Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk A51, Cleveland, OH 44195, USA
    J Am Soc Nephrol 16:3027-37. 2005
    ..There was no correlation between diastolic BP and renal outcomes. We recommend a SBP target between 120 and 130 mmHg, in conjunction with blockade of the renin-angiotensin system, in patients with type 2 diabetic nephropathy...
  79. ncbi Weight loss reduces tissue factor in morbidly obese patients
    Christoph W Kopp
    2nd Department of Medicine, Angiology Division, University of Vienna, General Hospital AKH, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Obes Res 11:950-6. 2003
    ..To investigate the tissue factor (TF) pathway in clinical obesity and associated metabolic syndrome...
  80. doi Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial
    Anne Katrin Sjølie
    Department of Ophthalmology, Odense University Hospital, Odense, Denmark
    Lancet 372:1385-93. 2008
    ..Diabetic retinopathy remains a leading cause of visual loss in people of working age. We examined whether candesartan treatment could slow the progression and, secondly, induce regression of retinopathy in people with type 2 diabetes...
  81. ncbi Case studies: reducing risk in patients with diabetes
    Michel Komajda
    Institut de Cardiologie, Hopital Pitie Salpetriere, Universite Pierre et Marie Curie, Paris, France
    Drugs Today (Barc) 42:37-41. 2006
  82. ncbi Impaired primary immune response in type-1 diabetes. Functional impairment at the level of APCs and T-cells
    Martin Spatz
    Biomedizinische ForschungsgmbH, Schwarzspanierstrasse 15 1 19, A 1090 Vienna, Austria
    Cell Immunol 221:15-26. 2003
    ....
  83. ncbi Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
    Lars Ryden
    Department of Cardiology, Karolinska University Hospital, Sweden
    Eur Heart J 28:88-136. 2007
  84. ncbi Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
    John A Dormandy
    Department of Clinical Vascular Research, Ingelby House, St Georges Hospital, Blackshaw Road, London SW17 0QT, UK
    Lancet 366:1279-89. 2005
    ..Our aim, therefore, was to ascertain whether pioglitazone reduces macrovascular morbidity and mortality in high-risk patients with type 2 diabetes...
  85. ncbi Time to insulin initiation cannot be used in defining latent autoimmune diabetes in adults
    Sinead Brophy
    School of Medicine, Swansea University, Swansea SA2 8PP, UK
    Diabetes Care 31:439-41. 2008
    ..Latent autoimmune diabetes in adults is type 1 diabetes presenting as non-insulin dependent diabetes. One feature of the selection criteria is time independent of insulin treatment. We examine the validity of this criterion...